

Does have autologous bloodwithdrawal with or without sequestration effect on the usage of allogeneic bloodproducts during heartsurgery?

Gepubliceerd: 15-12-2008 Laatste bijgewerkt: 18-08-2022

We expect that after autologous bloodwithdrawal followed by plasma sequestration before the autologous transfusion, the usage of allogeneic bloodproducts will be diminished.

Ethische beoordeling	Niet van toepassing
Status	Werving nog niet gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON26094

Bron

NTR

Verkorte titel

Sequestration Study

Aandoening

heartsurgery

CPB

autologous bloodwithdrawal

sequestration

allogeneic bloodproducts

Ondersteuning

Primaire sponsor: N/A

Overige ondersteuning: N/A

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

Will the usage of allogeneic bloodproducts be deminished after sequestration?

Toelichting onderzoek

Achtergrond van het onderzoek

Background of this study:

Preoperative, during induction of anaesthesia, autologous blood is withdrawn and afterward is given back after cardio-pulmonary-bypass (CPB), because of the presumed benefit on haemostasis.

The consequence of the blood withdrawal before CPB is not seldom low Hematocrit (Ht) during bypass and allogeneic red blood cells (RBC's) need to be added to gain a target level of Ht.

Transfusion of RBC's could be avoided when sequestration of the autologous blood is applied. During sequestration blood cells are separated from the plasma.

The autologous RBC's will be given back to the patient immediately after withdrawing; the platelets and plasma can be given to the patient after CPB cessation and protamine administration.

To examine the results of autologous blood withdrawal on patients with a normal Hb/Ht a prospective, randomized study will be performed.

The hypothesis is that sequestration of autologous blood will result in less transfusion of allogeneic blood products.

Primarily will be investigated the amount of allogeneic blood products transfusion and the coagulation of the patient.

When the outcome will be positive: the treatment can be in the follow-up study validated for the patient with a smaller body surface.

Purpose of this study:

When it is possible to prove that there is a significant difference between the sequestration group and the other two groups, it also will be possible for patients with a smaller body surface to donate autologous blood and also this group will need also less allogeneic blood products.

Study set-up:

There will be 3 groups of patients.
Each group will consist of 34 patients.

Group 1. autologous blood withdrawal.

Group 2. autologous blood withdrawal with sequestration.

Group 3. control group.

In group 1 autologous blood is withdrawn during induction of anesthesia and is given back to the patient after administration of protamine. Till that time it will be kept on good condition on 37 degrees Celsius.

In group 2 autologous blood is withdrawn and sequestration will take place immediately. After sequestration the RBC will be given back to the patient; the plasma and platelets will be given back to the patient after CPB and will be kept on a gentle shaker.

In group 3 there will be no withdrawing of autologous blood.

In all groups the rest volume will be handled the same with auto transfusion apparatus as usually.

The volume what is declined is replaced by colloid solution.

Study population:

Inclusion criteria:

1. >18 years;
2. body surface > 170 dm²;
3. Primary CABG and/or AVR procedure;
4. Hb/Ht level which will be no lower than

0.20 l/l after calculation for autologous blood withdrawing.

Exclusion criteria:

1. trombocytes count of $<120(x10^9/l)$.

Pre operative:

1. increased liver enzymes (ALAT/ASAT/AF);
2. very poor Left Ventricle function;
3. impaired renal function (Kreatinine of >120 mmol/l;
4. COPD;
5. Reoperation.

Primary study variables/results:

Is there a decrease in use of allogeneic blood products in the sequestration group?

Secondary examination result:

Is there a decrease of blood loss in the sequestration group in regards to the blood loss of the other two groups?

Description and estimation of load and risks:

Load:

Extra time to explain and inform the patient of this study and for signing the informed consent.

Risk:

No extra risk.

Doel van het onderzoek

We expect that after autologous bloodwithdrawal followed by plasma sequestration before the autologous transfusion, the usage of allogeneic bloodproducts will be deminished.

Onderzoeksopzet

Induction, return of RBC immediately after sequestration, return of trombocytes at the end of CPB.

End time operation, time point 4 hours after entry ICU. Removal drains.

Onderzoeksproduct en/of interventie

Group 1:

autologous bloodwithdrawal (500ml-1000ml) during induction of anesthesia.

The blood will be saved in bloodbags Compoflex (Fresenius). These bloodbags will contain CPDA (citrate-phosphate-dextrose-adenine) necessary to prevent soldification of the autologous blood. Blood will be kept on the "shudder" at 37 degrees Celcius until the end of the CPB. After CPB it will be given back (autologous transfusion) after administration of protamine.

Group 2:

autologous bloodwithdrawal (500ml-1000ml) during the induction of the anesthesia.

Immedialely followed by sequestration and return of the RBC. The plasma and Trombocytes will be given back to the patient after CPB. This blood will be kept in bloodbags Compoflex (Fresenius). These bloodbags will contain CPDA (citrate-phosphate-dextrose-adenine) necessary to prevent soldification of the autologous blood. By this sequestration group, blood will be prepared with the autotransfusion apparatus Electa(Sorin Group). With the help of a sequestration set Trombocytes will be kept on the "shudder" (a gently shaker).

Group 3:

control group (no autologous blood withdrawal).

Contactpersonen

Publiek

Erasmus University Medical Center
PO Box 2040

L. Duininck
Dept. Cardio-Thoracic Surgery, Bd-563
Erasmus University Medical Center
Rotterdam
Rotterdam 3000 CA
The Netherlands
+31 10 70 32 150

Wetenschappelijk

Erasmus University Medical Center
PO Box 2040

L. Duininck
Dept. Cardio-Thoracic Surgery, Bd-563
Erasmus University Medical Center
Rotterdam
Rotterdam 3000 CA
The Netherlands
+31 10 70 32 150

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Patients with a BSA > 170 dm²;
2. Patients who need to undergo CABG and or Valve surgery;
3. Patients with a Hemoglobin/Hematocrit ratio >0.20 l/l after calculation with the formula for bloodwithdrawal.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. Patients with a Hemoglobin/Hematocrit ratio < 0.20 l/l after calculation with the formula for bloodwithdrawal;
2. Patients with a preoperative Trombocyt count of < 120 ($\times 10^9/L$);
3. Patients with increased liverenzymes (ALAT/ASAT/AF $> 2,5$ ULN);
4. Patients with a moderate or poor left ventricle function;
5. Patients with impaired renal function (Kreatinine > 120 ($\mu\text{mol/l}$));
6. Patients who need to have a reoperation;
7. Patients with COPD.

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	Gerandomiseerd
Blinding:	Enkelblind
Controle:	Geneesmiddel

Deelname

Nederland	
Status:	Werving nog niet gestart
(Verwachte) startdatum:	01-03-2009
Aantal proefpersonen:	102
Type:	Verwachte startdatum

Ethische beoordeling

Niet van toepassing

Soort:

Niet van toepassing

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL1519
NTR-old	NTR1589
Ander register	: Thchoz 2008-11
ISRCTN	ISRCTN wordt niet meer aangevraagd

Resultaten

Samenvatting resultaten

REFERENCES:

1. Okamura T. Koh.E.Yokoyama S. Effect of autologous plate-rich plasma (PRP) in cardiac surgery. Kyobu Geka. 2001 May; 54 (5): 397-400

2. Stover E.P. Siegel LC, Hood PA, O; Riordan GE. McKenna TR. Platelet-riche plasma sequestration, with therapeutic platelet yields, reduces allogenic in complex cardiac surgery. Anesth Analg. 2000 Mar; 90(3):509-16.

3. Safwat AM, Bush R, Prevec W.Reitan JA. Intraoperative use of platelet-plasmapheresis in vascular surgery. J.Clin Anest.2002 Feb; 14(1):10-4.

4. Koster A. Sanger S.KnörigFJ Kuppe H.Hetzer R Loebe. Autologous plasma and platelet sequestration at the beginning of cardiopulmonary bypass: a pilot investigation in five patients undergoing extended vascular surgery in deep hypothermia. ASAIO Journal Jan/Feb 2002.48(1): 106-109.

5. Hiramatsu T.Okamura T.Imai Y.KurosawaH Aoki M.Shinóka T.Takanashi Y.Effects of autologous platelet concentrate reinfusion after open heart surgery in patient with congenital

heart disease. Ann Thorac Surg. Apr. 2002; 73(4): 1282-5.

6. Alfred H.Stammers,BS,CCP, John Kratz,MD, Timothy Johnson BS, Jack Crumbley, MD, and Jon Merril, BS, CCP.

Journal of Extra-Corporeal Technology; 1993, 25(1)6-13.

7. Crowter M, Ford I, Jeffrey RR, Urbaniak SJ, Greaves. Quality of harvested autologous platelets compared with stored donor platelets for use after cardiopulmonary bypass procedures.Br.J.Haematol. 2000 Oct; 111(1): 175-91

8.R.Daane Toepasbaarheid van de plasma sequestratie techniek binnen de cardiochirurgie in het Amphia ziekenhuis Breda. NeSecc Journaal editie 2007(2) p26.

9. T.Menges, I.Welters,R.M Wagner,J.Bolt, F.Dapper,G.Hempelmann. The influence of acute preoperative plasmapheresis on coagulation test, fibrinolysis, bloodloss and transfusion requirements in cardiac surgery. European J. of Cardio-Thoracic Surg. 11 (1997) 557-563.

10.J.W.H. van Hees. Het effect van peri-operatieve plasmaferese bij langdurige cardiochirurgische ingrepen.